Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tianeptine - Servier

Drug Profile

Tianeptine - Servier

Alternative Names: Coaxil; Stablon; Tatinol

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator French Society of Medical Research
  • Developer Servier; Vela Pharmaceuticals
  • Class Anxiolytics; Nootropics; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action AMPA receptor modulators; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alcoholism; Anxiety disorders; Major depressive disorder
  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 15 Feb 2019 No development reported - Phase-III for Major depressive disorder (In the elderly) in Bulgaria, Estonia, Finland, Slovakia (PO, capsule)
  • 07 Aug 2018 Launched for Major depressive disorder in China (PO)
  • 01 Jan 2016 Servier completes a phase III trial in Major depressive disorder (In the elderly) in Slovakia, Finland, Estonia, Bulgaria (PO) (EudraCT2012-005612-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top